IMA 910

Drug Profile

IMA 910

Alternative Names: Colorectal cancer vaccine - immatics; IMA910

Latest Information Update: 29 Sep 2015

Price : $50

At a glance

  • Originator immatics biotechnologies GmbH
  • Class Cancer vaccines; Peptide vaccines; Peptides
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Colorectal cancer

Highest Development Phases

  • No development reported Colorectal cancer

Most Recent Events

  • 29 Sep 2015 No recent reports on development identified - Phase-I/II for Colorectal cancer (Combination therapy, Late-stage disease, Treatment-experienced) in Belgium, Bulgaria, Germany, Hungary, Latvia, Poland, Romania, Serbia and United Kingdom (Intradermal)
  • 24 Jan 2012 Efficacy and adverse events data from a phase I/II trial in Colorectal cancer (treatment-experienced patients, combination therapy, late-stage disease) released by immatics biotechnologies
  • 31 Dec 2011 immatics completes a phase I/II trial in Colorectal cancer (treatment-experienced patients, combination therapy, late-stage disease) in Europe (NCT00785122)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top